Shockwave Medical: A Look Into Q1 Financials And Value To Johnson & Johnson Investors


  • Johnson & Johnson’s acquisition of Shockwave Medical is expected to benefit J&J’s investors due to positive trends in sales, revenue, and cash flow.
  • Shockwave Medical has a strong product portfolio and a growing market value in the intravascular lithotripsy (IVL) technology.
  • The merger will expand J&J’s presence in the cardiovascular intervention market and prevent competitors from acquiring SWAV’s technology.

Coronary arteries

7activestudio/iStock via Getty Images


Considering Shockwave Medical’s (NASDAQ:SWAV) latest Q1 2024 report, which revealed positive trends in sales, revenue and cash flow, the increasing market value and adoption of the intravascular lithotripsy (IVL) technology, together with the positive results of the

Analyst’s Disclosure: I/we have a beneficial long position in the shares of JNJ either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Leave a Reply

Your email address will not be published. Required fields are marked *